leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.
(
CSE:AGNOTCQB:AGNPF
)

Algernon Pharmaceuticals updates on progress of Phase 2b final data from coronavirus trial

The company confirmed a "significant number of patients in the study did receive some form of an imaging scan as part of their release protocol from the hospital"

Algernon Pharmaceuticals Inc. -
Earlier this year, Algernon said that if the final set of data was positive, it would look to get EUA from the US FDA

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), the drug repurposing company, updated on the progress of releasing its final data set from the Phase 2b part of its Phase 2b/3  trial to assess Ifenprodil as a potential coronavirus (COVID-19) treatment. 

"The company reports that due to a fire at the Romanian Hospital site, there was a delay in completing the site audit as planned," Algernon said in a statement on Wednesday. 

READ: Algernon Pharmaceuticals mulls lung scarring as additional endpoint for Phase 2b/3 coronavirus trial of Ifenprodil

"However the company is pleased to report that the source data audit from all sites and for all patients is now complete. The database will be locked for analysis on March 5th and the company will update the market on the final data release shortly thereafter," it added.

In addition, the company confirmed that a "significant number of patients in the study did receive some form of an imaging scan as part of their release protocol from the hospital".

"While Algernon believes the data may be helpful in establishing Ifenprodil’s possible role in reducing post-COVID infection lung scarring, in order to ensure the final data process is not delayed further, the data will be reviewed as supplemental, at a later date," it said.

Earlier this year, Algernon said that if the final set of data was positive, it would look to get emergency use authorization (EUA) from the US FDA.

A Phase 3 trial would be required regardless of whether or not it receives an EUA.

Algernon reckons Ifenprodil may reduce the infiltration of neutrophils and T-cells into the lungs, where they can release glutamate and cytokines respectively.

The latter can result in the problematic so-called cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in coronavirus infected patients.

Contact the author at giles@proactiveinvestors.com

Quick facts: Algernon Pharmaceuticals Inc.

Follow
CSE:AGN

Price: 0.09 CAD

Market Cap: $15.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has confirmed in a preclinical study, that increased the growth of cortical neurons by 40% with statistical significance in one arm of the study. That was achieved with a sub...

2 weeks, 2 days ago

2 min read